News

TMCnet3d
CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment
WARREN, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that CD8 Technology Services LLC (“CD8”) has signed a letter of ...
Nasdaq16d
Tevogen Bio Secures Agreement with CD8 Technology Services for In-House Cell Therapy Production Facility
Tevogen's CEO, Ryan Saadi, emphasized this milestone as a significant advancement in supporting the company's pipeline of off-the-shelf, genetically unmodified CD8+ T cell therapeutics.
Yahoo Finance4d
CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment
CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment Tevogen Bio Inc Wed, Apr 30, 2025, 3:49 PM 3 min read ...
Mena FN4d
CD8 Technology Signs Letter Of Intent For Tevogen Bio’S In-House Manufacturing Facility, Marking First Phase Of Up To $50 Million Commitment
(MENAFN- GlobeNewsWire - Nasdaq) WARREN, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or“Company”) (Nasdaq: TVGN ) today ...